About Zoledronic Acid API
Therapeutic CategoryAnti-Cancer/ Oncology

CAS Number
118072-93-8
API Technology
Synthetic
Dose Form
Injectable
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, EUDMF, Russia DMF
Mechanism of Action
Zoledronic acid slows down bone resorption, allowing the bone-forming cells time to rebuild normal bone and allowing bone remodeling
Indication
Reclast is a bisphosphonate indicated for:
- Treatment and prevention of postmenopausal osteoporosis
- Treatment to increase bone mass in men with osteoporosis
- Treatment and prevention of glucocorticoid-induced osteoporosis
- Treatment of Paget’s disease of bone in men and women
Zometa is a bisphosphonate indicated for the treatment of:
- Hypercalcemia of malignancy.
- Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy
Related APIs
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!